Gut microbiome lab launched at Hyderabad hospital to advance research into IBD
AIG Hospitals in Hyderabad has launched a specialized laboratory dedicated to researching the human gut microbiome and developing oral capsule formulations. The facility focuses on treating inflammatory bowel diseases like ulcerative colitis and Crohn’s disease through scientific donor screening and clinical research protocols.
Why it matters
This initiative represents a significant step in personalized medicine, potentially offering new therapeutic avenues for chronic inflammatory conditions that are resistant to conventional treatments.
AIG Hospitals, Hyderabad on Saturday (August 29) launched a dedicated Gut Microbiome Therapeutics and Pill Lab to study the therapeutic potential of the human gut microbiome, with an initial focus on inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.
The platform will work on developing oral microbiome capsule formulations using scientifically screened donor material. The process will include microbiome profiling, controlled sample processing, preservation, capsule formulation, quality and safety checks, and clinical research protocols.
The hospital clarified that the microbiome pill being developed at the facility is strictly for research purposes and will be used only as part of approved clinical research programmes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in